Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis | JCAD | The Journal of Clinical and Aesthetic Dermatology
J Clin Aesthet Dermatol. 2024;17(10):63–67. by Juan Gabriel Vasquez, MD; Jayme M. Heim, MSN, FNP-BC; Tina Bhutani, MD, MAS; John Koo, MD; Jacob Mathew, PharmD, MBA; Thomas Ferro, MD; and Neal Bhatia, MD Dr. Vasquez and Ms. Heim are with West Michigan Dermatology in Grandville, Michigan. Drs. Bhutani and Koo are with the University of California San Francisco Health in San Francisco, California. Drs. Mathew and Ferro are with Sun Pharmaceutical Industries, Inc. in Princeton, New Jersey. Dr. Bhatia is with Therapeutics Clinical Research in San Diego, California. FUNDING: This study and preparation of this article was funded by Sun Pharmaceuticals. DISCLOSURES: Ms. Heim has been a speaker, adviser, and consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, and Novartis; an adviser for Galderma, Mayne Pharma, Regeneron Pharmaceuticals, and Sanofi; an adviser and consultant for Ortho Dermatologics; and a speaker and adviser for Beiersdorf, Incyte, LEO Pharma, and S